Innate Pharma
IPHA
4 hedge funds and large institutions have $5.71M invested in Innate Pharma in 2020 Q4 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
0.37% less ownership
Funds ownership: 2.13% → 1.77% (-0.37%)
10% less capital invested
Capital invested by funds: $6.36M → $5.71M (-$657K)
33% less funds holding
Funds holding: 6 → 4 (-2)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$15.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$960K |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$97.8K |
| 3 |
Millennium Management
New York
|
-$80K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Wellington Management Group
Boston,
Massachusetts
| $5.46M | -$97.8K | -21,945 | -2% |
|
|
2
Millennium Management
New York
| $224K | -$80K | -17,960 | -25% |
|
|
3
Morgan Stanley
New York
| $21K | +$15.9K | +3,559 | +227% |
|
|
SPIA
4
Steward Partners Investment Advisory
New York
| $4K | – | – | – |
|
|
RCMNY
5
Rubric Capital Management (New York)
New York
| – | -$960K | -250,000 | Closed |
|
|
6
Osaic Holdings
Scottsdale,
Arizona
| – | -$8K | -2,000 | Closed |
|
IPHA Hedge Fund Activity: Q4 2020 in Review
4 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q4 2020, worth a combined $5.71M — down 10% from $6.36M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of IPHA and 0 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 1 added.
The largest buyer was Morgan Stanley, adding an estimated $15.9K. The largest seller was Rubric Capital Management (New York), exiting entirely with an estimated $960K sold.
- 4 institutional investors held Innate Pharma (IPHA) as of Q4 2020, down from 6 in Q3 2020.
- Funds reported $5.71M of Innate Pharma stock for Q4 2020, down 10% quarter-over-quarter.
- 0 funds opened new Innate Pharma positions in Q4 2020 and 2 closed out, a net change of -2 holders.
- The largest Innate Pharma buyer in Q4 2020 was Morgan Stanley, an estimated $15.9K added.
- The largest Innate Pharma seller in Q4 2020 was Rubric Capital Management (New York), an estimated $960K sold.
Based on aggregated 13F filings for Q4 2020.